News
Feed
Events
Feed
News
+ Events
Feed

Immunic AG

  • ISIN US4525EP1011
  • Country Deutschland

Latest News

29 October 2024

11:30 Corporate

Immunic AG

Corporate

Immunic to Participate in Industry, Scientific and Investor Conferences in November

22 October 2024

12:30 Corporate

Immunic AG

Corporate

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

18 September 2024

12:30 Corporate

Immunic AG

Corporate

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

4 September 2024

12:30 Corporate

Immunic AG

Corporate

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

28 August 2024

12:30 Corporate

Immunic AG

Corporate

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

8 August 2024

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

1 August 2024

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

24 July 2024

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (news with additional features)

9 July 2024

12:30 Corporate

Immunic AG

Corporate

Immunic Appoints Jason Tardio as Chief Operating Officer and President (news with additional features)

28 May 2024

12:30 Corporate

Immunic AG

Corporate

Immunic to Participate in Industry and Scientific Conferences in June

8 May 2024

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

6 May 2024

12:30 Corporate

Immunic AG

Corporate

Immunic to Participate in Investor and Scientific Conferences in May

1 May 2024

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

30 April 2024

12:30 Corporate

Immunic AG

Corporate

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

4 April 2024

12:30 Corporate

Immunic AG

Corporate

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

20 March 2024

11:30 Corporate

Immunic AG

Corporate

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

7 March 2024

12:30 Corporate

Immunic AG

Corporate

Immunic to Participate in Investor and Scientific Conferences in March

29 February 2024

12:30 Corporate

Immunic AG

Corporate

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

22 February 2024

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

15 February 2024

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

1 February 2024

12:30 Corporate

Immunic AG

Corporate

Immunic to Participate in Investor and Scientific Conferences in February

5 January 2024

12:35 Corporate

Immunic AG

Corporate

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

12:30 Corporate

Immunic AG

Corporate

Immunic, Inc. Announces Private Placement of up to $240 Million

21 November 2023

12:30 Corporate

Immunic AG

Corporate

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dosing Regimens in Multiple Sclerosis

2 November 2023

11:30 Corporate

Immunic AG

Corporate

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

26 October 2023

12:30 Corporate

Immunic AG

Corporate

Immunic to Participate in Scientific and Industry Conferences in November

16 October 2023

12:30 Corporate

Immunic AG

Corporate

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

15 October 2023

12:30 Corporate

Immunic AG

Corporate

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

11 October 2023

12:30 Corporate

Immunic AG

Corporate

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

9 October 2023

22:01 Corporate

Immunic AG

Corporate

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Upcoming Events

No Events found